Gyu Rak Chon

Gyu Rak Chon

Auto-generated profile, based on publicly available information

Gyu Rak Chon

Department of Internal Medicine, Konkuk University Chungju Hospital, Konkuk University School of Medicine, Chungju, Korea

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JLJung Yeon Lee
Jung Yeon Lee
GCGyu Rak Chon
Gyu Rak Chon
Chin Kook RheeChin Kook Rhee
Chin Kook Rhee
DKDeog Kyeom Kim
Deog Kyeom Kim
HYHyoung Kyu Yoon
Hyoung Kyu Yoon
KJKi Suck Jung
Ki Suck Jung
Lee JY, et al. J Korean Med Sci. 2016 Apr;31(4):553-560. https://doi.org/10.3346/jkms.2016.31.4.553

1 December 2011 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
WKWon-Young Kim
Won-Young Kim
GSGee Young Suh
Gee Young Suh
JHJin Won Huh
Jin Won Huh
SKSung-Han Kim
Sung-Han Kim
MKMin-Ju Kim
Min-Ju Kim
FCfor the Korean Society of Critical Care Medicine (KSCCM) H1N1 Collaborative‡
for the Korean Society of Critical Care Medicine (KSCCM) H1N1 Collaborative‡
A recentin vitrostudy showed that the three compounds of antiviral drugs with different mechanisms of action (amantadine, ribavirin, and oseltamivir) could result in synergistic antiviral activity against influenza virus. However, no clinical studies have evaluated the efficacy and safety of combination antiviral therapy in patients with severe influenza illness. A total of 245 adult patients who were critically ill with confirmed pandemic influenza A/H1N1 2009 (pH1N1) virus infection and were admitted to one of the intensive care units of 28 hospitals in Korea were reviewed. Patients who required ventilator support and received either triple-combination antiviral drug (TCAD) therapy or oseltamivir monotherapy were analyzed. A total of 127 patients were included in our analysis. Among them, 24 patients received TCAD therapy, and 103 patients received oseltamivir monotherapy. The 14-day mortality was 17% in the TCAD group and 35% in the oseltamivir group (P= 0.08), and the 90-day mortality was 46% in the TCAD group and 59% in the oseltamivir group (P= 0.23). None of the toxicities attributable to antiviral drugs occurred in either group of our study, including hemolytic anemia and hepatic toxicities related to the use of ribavirin. Logistic regression analysis indicated that the odds ratio for the association of TCAD with 90-day mortality was 0.58 (95% confidence interval, 0.24 to 1.42;P= 0.24). Although this study was retrospective and did not provide virologic outcomes, our results suggest that the treatment outcome of the triple combination of amantadine, ribavirin, and oseltamivir was comparable to that of oseltamivir monotherapy.

1 June 2014 in Journal of Critical Care
Verified
Journal Article
Closed access
CPChi-Min Park
Chi-Min Park
YKYounsuck Koh
Younsuck Koh
KJKyeongman Jeon
Kyeongman Jeon
SNSungwon Na
Sungwon Na
CLChae-Man Lim
Chae-Man Lim
GSGee Young Suh
Gee Young Suh

1 July 2012 in Shock
Verified
Journal Article
Closed access
GCGyu Rak Chon
Gyu Rak Chon
JCJai Won Chang
Jai Won Chang
JHJin Won Huh
Jin Won Huh
CLChae-Man Lim
Chae-Man Lim
YKYounsuck Koh
Younsuck Koh
SHSang-Bum Hong
Sang-Bum Hong
We hypothesized that the time from sepsis to inception of continuous renal replacement therapy (CRRT) can be used to predict survival rates in patients with septic acute kidney injury (AKI). The survival predictability of CRRT inception time was compared with that of RIFLE criteria, which were previously used in clinical practice. We retrospectively analyzed outcomes in 55 patients with septic AKI admitted to the medical intensive care unit at Asan Medical Center (Seoul, Korea) between April 2009 and October 2010. These patients were stratified by the time of inception of CRRT from sepsis (early: ≤ 24 h and late: >24 h) and also by the RIFLE criteria (RIFLE-I and RIFLE-F). The primary outcome was 28-day mortality. Of the 55 patients, 38 (69.1%) were male. Patients' mean age was 62.6 years, the most common infection site was the lung (32, 58.2%), and 47 patients (85.5%) were on mechanical ventilation. Thirty patients (54.5%) were in the RIFLE-I, and the others were in the RIFLE-F. Twenty-eight-day mortality rates were lower in the early group than in the late group (19.4% vs. 47.4%; P = 0.03), but did not differ between RIFLE-I and RIFLE-F. Ventilator-free day at day 28 was longer in the early group than that in the late group (7.5 vs. 0 d; P = 0.033). After adjustment for covariates, we found that the late group (hazard ratio, 3.106; 95% confidence interval, 1.066-9.047) and Sequential Organ Failure Assessment at sepsis (hazard ratio, 1.410; 95% confidence interval, 1.108-1.796) were independent factors associated with 28-day mortality. This study suggests that the time interval from sepsis to CRRT inception may be a more useful predictor of 28-day mortality than RIFLE criteria in patients with septic AKI.

23 April 2013 in Respiratory Care
Verified
Journal Article
Closed access
PDF file
GCGyu Rak Chon
Gyu Rak Chon
JLJinmi Lee
Jinmi Lee
YSYujung Shin
Yujung Shin
JHJin Won Huh
Jin Won Huh
CLChae-Man Lim
Chae-Man Lim
SHSang-Bum Hong
Sang-Bum Hong
BACKGROUND: There are few studies of the epidemiology and clinical outcomes of patients with in-hospital cardiac arrest (IHCA) in a general hospital ward. OBJECTIVE: To investigate the clinical outcomes of IHCA cases that occurred in the general ward of a university hospital and that were witnessed and/or monitored. METHODS: We prospectively gathered data on all IHCAs in the general ward of Asan Medical Center, Seoul, South Korea, that were recorded by the Medical Emergency Team between March 2008 and February 2010. The main outcomes included survival to hospital discharge, incidence of IHCA, and prognostic factors related to hospital mortality. We also investigated preventable cases. RESULTS: We identified 238 index cases of IHCA. The average incidence of IHCA was 0.145 IHCAs per 1,000 patient admissions. Survival to hospital discharge was 19% (46 cases), 66% of which were due to non-cardiac causes, and 77% were due to medical illnesses. The most common first documented rhythm was pulseless electrical activity (38%). Two hundred three cases (85.3%) of IHCA were witnessed at the event; 135 cases (56.7%) were monitored at the event. Non-witnessed cases, monitored cases, night onset, medical illness, metastatic cancer, intubation, and long duration of cardiopulmonary resuscitation were significantly associated with hospital mortality. We identified 91 preventable cases (38%). Respiratory insufficiency (37 cases, 41%) was one of major cause of preventable IHCA. CONCLUSIONS: Witnessed IHCAs in the general ward had a higher rate of survival to hospital discharge; however, monitored cases had a lower rate of survival to hospital discharge. Respiratory insufficiency was a major preventable cause of IHCA. In consideration of the preventable IHCAs, further studies should be performed on monitoring practices in general wards.

31 August 2017 in Acute and Critical Care
Verified
Journal Article
Open access
PDF file
JCJae Woo Choi
Jae Woo Choi
YPYoung Sun Park
Young Sun Park
YLYoung Seok Lee
Young Seok Lee
YPYeonhee Park
Yeonhee Park
CCChaeuk Chung
Chaeuk Chung
JMJae Young Moon
Jae Young Moon
The Acute Physiology and Chronic Health Evaluation (APACHE) II model has been widely used in Korea. However, there have been few studies on the APACHE IV model in Korean intensive care units (ICUs). The aim of this study was to compare the ability of APACHE IV and APACHE II in predicting hospital mortality, and to investigate the ability of APACHE IV as a critical care triage criterion. The study was designed as a prospective cohort study. Measurements of discrimination and calibration were performed using the area under the receiver operating characteristic curve (AUROC) and the Hosmer-Lemeshow goodness-of-fit test respectively. We also calculated the standardized mortality ratio (SMR). The APACHE IV score, the Charlson Comorbidity index (CCI) score, acute respiratory distress syndrome, and unplanned ICU admissions were independently associated with hospital mortality. The calibration, discrimination, and SMR of APACHE IV were good (H = 7.67, P = 0.465; C = 3.42, P = 0.905; AUROC = 0.759; SMR = 1.00). However, the explanatory power of an APACHE IV score >93 alone on hospital mortality was low at 44.1%. The explanatory power was increased to 53.8% when the hospital mortality was predicted using a model that considers APACHE IV >93 scores, medical admission, and risk factors for CCI >3 coincidentally. However, the discriminative ability of the prediction model was unsatisfactory (C index <0.70). The APACHE IV presented good discrimination, calibration, and SMR for hospital mortality.